Efficacy of Favipiravir in treatment of mild & moderate COVID-19 infection in Nepal: a multi-center, randomized, open-labelled, phase III clinical trial

Adhikari et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.12.109, Mar 2022
Early treatmentRCT · 70 patients · Nepal · May – Oct 2020
Favipiravir for COVID-19
Outcome
Improvement
Relative Risk · 95% CI
Worse improvement with favipiravir
Not statistically significant · p = 0.57
Preliminary report for an RCT in Nepal with 38 favipiravir patients and 32 control patients, showing no significant differences. There were no serious side effects.
Potential risks of favipiravir include kidney injury1-3, liver injury2-5, cardiovascular events5,6, pulmonary toxicity6,7, and mutagenicity, carcinogenicity, teratogenicity, embryotoxicity, and the creation of dangerous variants8-14.
OutcomeImprovementEffect · pTreatmentControl
risk of no improvement 40.4% higher · RR 1.40 · p = 0.57 40.4% higherRR 1.40p = 0.57 10 of 38 (26.3%) 6 of 32 (18.8%) treatment 10 of 38 (26.3%), control 6 of 32 (18.8%)all
risk of no improvement 36.3% higher · RR 1.36 · p = 0.75 36.3% higherRR 1.36p = 0.75 8 of 27 (29.6%) 5 of 23 (21.7%) treatment 8 of 27 (29.6%), control 5 of 23 (21.7%)mild cases
risk of no improvement 63.6% higher · RR 1.64 · p = 1.00 63.6% higherRR 1.64p = 1.00 2 of 11 (18.2%) 1 of 9 (11.1%) treatment 2 of 11 (18.2%), control 1 of 9 (11.1%)moderate cases

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates.

Adhikari et al., 1 Mar 2022, Randomized Controlled Trial, Nepal, peer-reviewed, 12 authors, study period May 2020 - October 2020.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org November 2026 Nepal Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Vietnam Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Nigeria Taiwan Fiji Zambia Bosnia-Herzegovina Dominican Republic Bolivia Côte d'Ivoire Eritrea Togo Bulgaria Greece Slovakia Iceland New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel Haiti North Macedonia Hong Kong Qatar Panama Serbia Nepal favored high-profit treatments.The average efficacy of treatments was very low.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org November 2026 Nepal Angola Colombia Kenya Mozambique Myanmar South Africa Peru Philippines USA Brazil Vietnam Iran Bangladesh Ethiopia Ghana Germany Mexico South Korea United Kingdom Saudi Arabia Algeria Morocco Yemen Poland Uzbekistan India China Venezuela DR Congo Madagascar Thailand Uganda Egypt Taiwan Fiji Zambia Dominican Rep. Bolivia Côte d'Ivoire Eritrea Togo Sri Lanka Bulgaria Greece Slovakia New Zealand Trinidad and Tobago Mongolia Czechia Belarus Israel North Macedonia Hong Kong Qatar Panama Serbia Nepal favored high-profit treatments.The average efficacy was very low.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
High SARS-CoV-2 attack rates among asymptomatic hospital workers from Ecuador
D C Morales Jadan, A P Vallejo Janeta, M A Garcia Bereguiain
International Journal of Infectious Diseases, doi:10.1016/j.ijid.2021.12.107
Purpose: To determine the SARS-CoV-2 risk of infection in Ecuadorian hospital. This study aims to describe the SARS-CoV-2 attacks rate and viral loads among patient care workers and other staff from Ecuadorian hospitals during the first wave of COVID-19 pandemic. Methods & Materials: : Study design and setting. We carried out a cross-sectional study to describe the attack rate of SARS-CoV-2 infection among patient care workers (physicians, nurses and nursing assistants) and other healthcare personnel (administrative and services staff) from 9 hospitals of the Andean and Costal Regions of Ecuador from May to October 2020. Sample collection, RNA Extraction and RT-qPCR for SARS-CoV-2 diagnosis using the CDC protocol. The samples were processed in the BSL2 certified molecular biology laboratory at Universidad de Las Americas. Nasopharyngeal swabs were collected on 0.5mL TE pH 8 buffer for SARS-CoV-2 diagnosis by RT-qPCR following an adapted version of the CDC protocol. Statistical analysis. Chi cuadrado with the statistic program SPSS Results: A total of 1243 patient care workers and 428 of other healthcare staff were tested for SARS-CoV-2 infection. The SARS-CoV-2 attack rate was 12% (145/1243) for patient care workers and 19% (80/428) for other healthcare personnel, being this difference statistically significant (p < 0.05). For each hospital, the following SARS-CoV-2 attack rates were obtained for patient care workers and other staff: 35% and 50% in "Hogar ABEI", 21% and 26% in "Clínica Nuestra Señora de Guadalupe", 15% and 18% in "Hospital de Atención Integral al Adulto Mayor", 5% and 11% in "Hospital de Especialidades Eugenio Espejo", 12% and 22% in "Hospital Geriátrico Dr. Bolívar Arguello", 13% and 22% in "Hospital Dr. Gustavo Domínguez", 22% and 12% in "Hospital General Dr. Napoleón Dávila", 9% and 14% in "Hospital Pablo Arturo" and 5% and 13% in "Hospital San Francisco de Quito". Moreover, we found 47 individuals (19 among patient care workers and 28 among other staff) with viral loads larger than 10 8 copies/mL that may be considered super spreaders. Conclusion: Ecuadorian hospital workers at a high-risk group for SARS-CoV-2 infection. Regular SARS-CoV-2 testing should be mandatory for this group as even asymptomatic SARS-CoV-2 super spreaders can be detected.
DOI record: { "DOI": "10.1016/j.ijid.2021.12.109", "ISSN": [ "1201-9712" ], "URL": "http://dx.doi.org/10.1016/j.ijid.2021.12.109", "alternative-id": [ "S1201971221010018" ], "author": [ { "affiliation": [], "family": "Adhikari", "given": "P.", "sequence": "first" }, { "affiliation": [], "family": "Koirala", "given": "J.", "sequence": "additional" }, { "affiliation": [], "family": "Shrestha", "given": "A.", "sequence": "additional" }, { "affiliation": [], "family": "Bista", "given": "N.", "sequence": "additional" }, { "affiliation": [], "family": "Maleku", "given": "K.", "sequence": "additional" }, { "affiliation": [], "family": "Das", "given": "J.", "sequence": "additional" }, { "affiliation": [], "family": "Bhandari", "given": "K.", "sequence": "additional" }, { "affiliation": [], "family": "Adhikari", "given": "N.", "sequence": "additional" }, { "affiliation": [], "family": "Rawal", "given": "A.", "sequence": "additional" }, { "affiliation": [], "family": "Pandit", "given": "K.", "sequence": "additional" }, { "affiliation": [], "family": "Gyawali", "given": "P.", "sequence": "additional" }, { "affiliation": [], "family": "Pant", "given": "S.", "sequence": "additional" } ], "container-title": [ "International Journal of Infectious Diseases" ], "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2022, 2, 28 ] ], "date-time": "2022-02-28T23:44:43Z", "timestamp": 1646091883000 }, "deposited": { "date-parts": [ [ 2022, 2, 28 ] ], "date-time": "2022-02-28T23:44:44Z", "timestamp": 1646091884000 }, "indexed": { "date-parts": [ [ 2022, 3, 1 ] ], "date-time": "2022-03-01T00:12:48Z", "timestamp": 1646093568973 }, "is-referenced-by-count": 0, "issn-type": [ { "type": "print", "value": "1201-9712" } ], "issued": { "date-parts": [ [ 2022, 3 ] ] }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 3, 1 ] ], "date-time": "2022-03-01T00:00:00Z", "timestamp": 1646092800000 } }, { "URL": "http://creativecommons.org/licenses/by-nc-nd/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2021, 12, 12 ] ], "date-time": "2021-12-12T00:00:00Z", "timestamp": 1639267200000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S1201971221010018?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S1201971221010018?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "page": "S45-S46", "prefix": "10.1016", "published": { "date-parts": [ [ 2022, 3 ] ] }, "published-print": { "date-parts": [ [ 2022, 3 ] ] }, "publisher": "Elsevier BV", "reference-count": 0, "references-count": 0, "relation": {}, "resource": { "primary": { "URL": null } }, "score": 1, "short-container-title": [ "International Journal of Infectious Diseases" ], "short-title": [], "source": "Crossref", "subject": [ "Infectious Diseases", "Microbiology (medical)", "General Medicine" ], "subtitle": [], "title": [ "Efficacy of Favipiravir in treatment of mild &amp; moderate COVID-19 infection in Nepal: a multi-center, randomized, open-labelled, phase III clinical trial" ], "type": "journal-article", "volume": "116" }